Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, open-label, parallel group study designed to evaluate
efficacy and safety of fulvestrant followed, at progression, by examestane and everolimus
versus examestane and everolimus followed, at progression, by fulvestrant in postmenopausal
women with HR+ and HER2- LABC or MBC whose disease has progressed to NSAI in the adjuvant or
metastatic setting.